Shots:
- Stryker has received the US FDA 510(k) clearance for Sonopet 3, its latest ultrasonic bone & soft tissue removal platform developed with surgeon input for enhanced power, precision & versatility in tissue removal
- Sonopet 3 provides access to platform technologies incl. RISE (Reimagined Integrated Surgical Experience) for a connected surgical workflow and Pulse Control to help regulate resection of hard & soft tissues, supporting integration across surgical settings
- First clinical cases with Sonopet 3 are expected to begin in Oct 2026, with a full commercial launch anticipated later this fall
Ref: Stryker | Image: Stryker | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
